In the most comprehensive systematic review of HER2-targeted therapy to date, Giordano and colleagues evaluated all comparative phase III randomized trials, systematic reviews, and meta-analyses of patients with HER2-positive advanced breast cancer published through October 2012 [13]. Here, ERBB2 is linked to breast carcinoma.